Incap (ICP1V) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
6 Dec, 2025Deal rationale and strategic fit
Acquisition targets growth in Germany, Europe's largest EMS market, and leverages a rebounding economy and expanding defense sector.
Expands into design and development (ODM) services, enhancing value across the product lifecycle for both existing and new customers.
Strengthens presence in defense, railway, and medical technology sectors, with a balanced customer base and established facilities in Germany and Romania.
Diversifies customer portfolio and reduces dependency on single large accounts.
Expands and complements the acquirer's geographical footprint and engineering capacity in the DACH region.
Financial terms and conditions
Purchase price is €50 million equity value, payable at closing, with a potential earnout of up to €5 million based on 2026 EBITDA performance.
Transaction financed through own funds and a €30 million bank loan.
Lacon Group's net debt as of 2024 was €7.1 million.
Lacon Group's unaudited pro forma revenue for Jan–Oct 2025 was €57.2 million, with adjusted EBITDA of €6.7 million (11.8% margin).
Additional liabilities include a local term loan and a factoring financing facility.
Synergies and expected cost savings
Synergies expected from cross-selling, improved capacity utilization, and procurement efficiencies.
Enhanced and broader service offering anticipated to benefit customers of both companies.
Latest events from Incap
- Q2 2025 revenue grew sequentially, but guidance was cut amid FX and project delays.ICP1V
Q2 202527 Mar 2026 - Q1 2025 revenue up 1.6% to EUR 52.2M, EBIT margin 11%, outlook positive despite uncertainty.ICP1V
Q1 202527 Mar 2026 - Q3 2025 saw lower revenue but strong margins and a positive outlook for Q4.ICP1V
Q3 202527 Mar 2026 - 2025 saw lower revenue and profit, but strong balance sheet and growth via Lacon acquisition.ICP1V
Q4 202526 Feb 2026 - 2024 revenue is set to exceed 2023, with EBIT expected to remain stable year-over-year.ICP1V
Q2 20242 Feb 2026 - Q3 delivered strong growth, improved margins, and raised guidance amid market challenges.ICP1V
Q3 202418 Jan 2026 - Q4 revenue surged 39.7% with strong profitability and a positive outlook for 2025.ICP1V
Q4 20241 Dec 2025